Pangea Laboratory and Unilabs Launch Non-Invasive Bladder Cancer Test in Switzerland

Pangea Laboratory and Unilabs are partnering to launch the Bladder CARE Assay in Switzerland, a DNA-based, non-invasive epigenetic test for bladder cancer and UTUC. The assay uses DNA methylation biomarkers to identify these cancers from urine samples, which can be collected conveniently at home with the Pangea collection device. This collaboration brings a new, patient-friendly diagnostic tool to the region and aims to transform cancer detection with a rollout planned across Europe.

​

The Bladder CARE Assay offers high sensitivity and specificity, with negative predictive values exceeding 93%. It is intended to supplement existing diagnostic procedures for patients with haematuria and those at risk for bladder cancer and UTUC. Pangea Laboratory COO Dr. Yap Ching Chew noted that the collaboration supports the shared vision of reducing patient burden and improving diagnostic accuracy, while Unilabs Switzerland’s head of pathology and oncology, Patrick Bornand, emphasized the assay's potential to advance early detection and patient care.